4263 — Susmed Income Statement
0.000.00%
Last trade - 00:00- ¥9bn
- ¥5bn
- ¥343m
Annual income statement for Susmed, fiscal year end - June 30th, JPY millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 34.9 | 115 | 317 | 531 | 343 |
| Cost of Revenue | |||||
| Gross Profit | 33.3 | 106 | 306 | 523 | 331 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 203 | 454 | 562 | 584 | 707 |
| Operating Profit | -169 | -338 | -245 | -53.5 | -364 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -96.6 | -276 | -233 | -49.5 | -356 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -96.9 | -278 | -233 | -50.7 | -357 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -96.9 | -278 | -233 | -50.7 | -357 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -96.9 | -278 | -233 | -50.7 | -357 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5.91 | -17.7 | -13.8 | -2.89 | -21.4 |
| Dividends per Share |